April 25, 2022 -- Investment in the cell and gene therapy sector remains robust, despite the disruptions over the last several years due to the COVID-19 pandemic. That's one of the take-home messages from this week's Cell & Gene Meeting on the Mediterranean, according to ScienceBoard Vice President of Digital Media Sales Walt Schoenborn and reporter Melisande Rouger, who were on site in Barcelona, Spain.
A major emphasis has been made on seeing things from the patient perspective, including in the development of clinical trials for new cell and gene therapy treatments. What's more, partnership activity between vendors has continued at a robust pace. Still, major differences remain between the U.S. and Europe.
Click on the video below for more details from this year's meeting, which was sponsored by the Alliance for Regenerative Medicine.
Copyright © 2022 scienceboard.net